Semaglutide & Tirzepatide
GLP-1/MetabolicWeight-Loss / Metabolic
Incretin-based therapies improving satiety and glycemic control; tirzepatide also activates GIP.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- 1× weekly
- Last updated
- 12/14/2025
- Targets
- GLP-1 receptor (both)GIP receptor (tirzepatide)
Overview
Incretin-based therapies improving satiety and glycemic control; tirzepatide also activates GIP.
Protocol
- Dosage Range
- Semaglutide: 0.25→2.4 mg weekly; Tirzepatide: 2.5→10–15 mg weekly (titrate)
- Frequency
- 1× weekly
- Cycle
- Long-term use for obesity/diabetes; reassess periodically
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Incretin-based therapies improving satiety and glycemic control; tirzepatide also activates GIP.
Targets
GLP-1 receptor (both)GIP receptor (tirzepatide)
Studies are being curated for this entry.
Suggest a studyBenefits
Significant weight lossImproved glycemic markersAppetite suppression
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea/constipation
- Possible lean mass loss without resistance training
References
References coming soon.
Suggest a reference